Add-On Ramucirumab Increases PFS in East Asians With Advanced Gastric Cancer Add-On Ramucirumab Increases PFS in East Asians With Advanced Gastric Cancer

Adding ramucirumab to paclitaxel as second-line therapy for advanced gastric cancer boosts progression-free survival in East Asian patients, the RAINBOW-Asia trial shows.Reuters Health Information
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news